Zealand Pharma announces closing of collaboration and license agreement with Roche
Company announcement – No. 12 / 2025
Zealand Pharma announces closing of collaboration and license agreement with Roche
Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or 'Zealand Pharma') (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Roche announced on March 12, 2025 have been satisfied, including regulatory conditions, and the agreement has become effective.
'We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma's vision of becoming a key player in the future management of obesity. Roche ticked all the right boxes for what we were looking for in a partner and we look very much forward to working closely together to unlock the full potential of petrelintide to benefit people who are overweight or obese', said Adam Steensberg, Chief Executive Officer at Zealand Pharma.
# # #
About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit www.zealandpharma.com.
ContactsAdam Lange (Investors)Vice President, Investor Relations Zealand PharmaEmail: alange@zealandpharma.com
Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@zealandpharma.com
Anna Krassowska, PhD (Investors and Media) Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: akrassowska@zealandpharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
22 minutes ago
- Bloomberg
Novo Climbs After FT Reports Activist Parvus Amassed Stake
Novo Nordisk A/S shares rose to the highest level in more than two months after a report that activist hedge fund Parvus Asset Management has built a stake as the Danish drugmaker struggles to keep its lead in the obesity market. The stock climbed as much as 2.5% in early Copenhagen trading.
Bloomberg
22 minutes ago
- Bloomberg
Euro Could Reach $1.40 Within Two Years: Macro Hive
Macro Hive CEO Bilal Hafeez says the euro could reach $1.40 within one or two years. "There has to be an outlet somewhere for dollar weakness," Hafeez tells Bloomberg Television. FX options show growing appetite for medium-term euro upside. Markets now see nearly a 1-in-2 chance of the single currency trading above $1.20 by the end of 2027, a far cry from a year ago where there was talk of parity. (Source: Bloomberg)
Bloomberg
27 minutes ago
- Bloomberg
Bloomberg Daybreak: Europe 06/10/2025
Bloomberg Daybreak Europe is your essential morning viewing to stay ahead. Live from London, we set the agenda for your day, catching you up with overnight markets news from the US and Asia. And we'll tell you what matters for investors in Europe, giving you insight before trading begins. Today's guests: Sunaina Sinha Haldea, Global Head of Private Capital Advisory at Raymond James & Rodrigo Liang, Co-founder and CEO of SambaNova Systems. (Source: Bloomberg)
